This research will study patients who have combined hyperlipidemia (increased blood levels of cholesterol and triglycerides). The study aims to look at the effects of simvastatin (Zocor) an approved drug for the treatment of hypercholesterolemia in patients who have elevated levels of blood cholesterol and concurrently moderately increased levels of blood triglycerides. Ten to twelve patients will be enrolled in the study at OHSU and it is planned to study a total of 50-60 patients at other participating centers in the United States. The purpose of this study is to assess how the body uses fats that may be eaten during the day and how the cholesterol-lowering drug simvastatin (Zocor) may reduce these fats in the blood after a fat-rich meal similar to a large milk-shake. We are also interested in assessing the effects of simvastatin on the body's production of cholesterol which will be measured by determination of the concentrations of a precursor of cholesterol which is excreted in the urine and how treatment with simvastatin affects the ability of white blood cells to take up cholesterol from the blood. We are also interested in measuring two enzymes known as lipoprotein lipase and hepatic lipase, which are responsible for the removal of the particles in the blood stream that contain cholesterol and other fats including new fat that enters the body after people have eaten a meal. We are trying to find out if treatment with simvastatin in addition to reducing concentrations of LDL cholesterol and triglyceride-rich lipoproteins can enhance clearance of fatty particles from the blood stream after ingestion of a fatty meal. These cholesterol-rich lipoproteins may increase the risk of developing atherosclerosis (the most common form of heart disease) and if simvastatin is shown to enhance their clearance this would be potentially of therapeutic benefit in reducing the risk of heart disease in patients with high blood levels of cholesterol and triglycerides. Until recently the maximal recommended dose of simvastatin for use in the treatment of hypercholesterolemia was 40 mg per day but a higher dose (80 mg per day) was approved in July 1998 by the FDA for the treatment of hypercholesterolemia and has been given to about 1,500 patients for a period of up to one year with a good safety profile. Participants in this study will receive three treatment periods, one of which will be a placebo, one will be simvastatin 20 mg per day and the third will be simvastatin 80 mg per day. Neither the participant nor the investigators will know which treatment is received although this information can be available if medically necessary. Participants will be asked to take two tablets of medications (a combination of simvastatin and placebo) once daily in the evening for a total period of 24 weeks.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000334-35
Application #
6418918
Study Section
Special Emphasis Panel (ZRR1)
Project Start
2000-12-01
Project End
2001-11-30
Budget Start
Budget End
Support Year
35
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Brenowitz, Willa D; Keene, C Dirk; Hawes, Stephen E et al. (2017) Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. Neurobiol Aging 53:83-92
Brenowitz, Willa D; Hubbard, Rebecca A; Keene, C Dirk et al. (2017) Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. Alzheimers Dement 13:654-662
Bergstrom, Colin P; Ruffell, Brian; Ho, Christine M T et al. (2017) Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates. Anticancer Drugs 28:120-126
Narayanan, Kumar; Uy-Evanado, Audrey; Teodorescu, Carmen et al. (2016) Mitral valve prolapse and sudden cardiac arrest in the community. Heart Rhythm 13:498-503
Abner, Erin L; Nelson, Peter T; Kryscio, Richard J et al. (2016) Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology. Alzheimers Dement 12:882-9
Sylwester, Andrew; Nambiar, Kate Z; Caserta, Stefano et al. (2016) A new perspective of the structural complexity of HCMV-specific T-cell responses. Mech Ageing Dev 158:14-22
Elliot, Diane; Garg, Bharti; Kuehl, Kerry et al. (2015) Why Are Women Law Enforcement Officers More Burned-Out and What Might Help Them? Occup Med Health Aff 3:
Samuels, Mary H (2014) Psychiatric and cognitive manifestations of hypothyroidism. Curr Opin Endocrinol Diabetes Obes 21:377-83
Redig, Jennifer K; Fouad, Gameil T; Babcock, Darcie et al. (2014) Allelic Interaction between CRELD1 and VEGFA in the Pathogenesis of Cardiac Atrioventricular Septal Defects. AIMS Genet 1:1-19
Lee, David S H; Markwardt, Sheila; Goeres, Leah et al. (2014) Statins and physical activity in older men: the osteoporotic fractures in men study. JAMA Intern Med 174:1263-70

Showing the most recent 10 out of 336 publications